Email This Article

FDA Panel Rejects Cephalon's Sparlon
By Robert Steyer
03/23/06 - 07:28 PM EST
The company is dealt a serious blow as experts say the ADHD drug poses too many risks.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,384.67 1,108.54 2,195.56 33.62
Oil *
78.46
UP
114.20
UP
15.06
UP
27.68
DOWN
0.67
10 Yr
3.36%
SPDR Gold
110.89
+1.11%
+1.38%
+1.28%
-1.95%
Data delayed 20 minutes

Brokerage Partners